Cumulative Fraction of Response for Once- and Twice-Daily Delamanid in Patients with Pulmonary Multidrug-Resistant Tuberculosis
Suresh Mallikaarjun(Pharmaceutical Product Development (United States)), Yongge Liu(Pharmaceutical Product Development (United States)), Shashikant Srivastava(The University of Texas at Tyler), Tawanda Gumbo(Raptamer Discovery Group (United States)), Devyani Deshpande, Lawrence Geiter(Pharmaceutical Product Development (United States)), Yusuke Inoue(Gunma University), Moti Chapagain, Alexander Berg(Critical Path Institute), Jeffrey Hafkin(Otsuka (United States)), Norimitsu Hariguchi(Otsuka (Japan)), Xiaofeng Wang(Pharmaceutical Product Development (United States)), T. Sasaki(Otsuka (Japan)), Makoto Matsumoto(Tottori University Hospital), Kuniko Hirota(Otsuka (Japan))
Cited by 24
Related Papers
A Toll-like receptor recognizes bacterial DNA
|Nature|2000|6.4k
HTLV-I ASSOCIATED MYELOPATHY, A NEW CLINICAL ENTITY
|The Lancet|1986|2.4k
Targeted Disruption of the MyD88 Gene Results in Loss of IL-1- and IL-18-Mediated Function
|Immunity|1998|2k
Essential role of Stat6 in IL-4 signalling
|Nature|1996|1.6k
Targeted disruption of the mouse <i>Stat3</i> gene leads to early embryonic lethality
|Proceedings of the National Academy of Sciences|1997|1.3k